|Bid||0.00 x 800|
|Ask||0.00 x 800|
|Day's Range||6.04 - 6.23|
|52 Week Range||3.36 - 11.56|
|Beta (5Y Monthly)||0.96|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 09, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||13.00|
Subscribe to Yahoo Finance Plus to view Fair Value for MXCT
Insiders who acquired US$166k worth of MaxCyte, Inc.'s ( LON:MXCT ) stock at an average price of US$8.29 in the past 12...
MaxCyte, Inc. (MXCT) delivered earnings and revenue surprises of 33.33% and 2.34%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support innovative, cell-based research, today announced financial results for the third quarter ended September 30, 2022.